Cannabis use was linked to treatment-resistant schizophrenia in a Pakistani hospital cohort
Among 230 schizophrenia patients in Pakistan, ongoing cannabis use was significantly associated with treatment resistance, defined as failure to respond to two adequate antipsychotic trials, even after excluding non-adherent patients.
Quick Facts
What This Study Found
The treatment resistance rate was over 60% in this cohort. Ongoing cannabis use was significantly associated with treatment resistance after controlling for treatment adherence. The study excluded cases where non-adherence could explain treatment failure, strengthening the cannabis-treatment resistance link.
Key Numbers
230 patients studied. Over 90% male. Treatment resistance rate: >60%. Cannabis use was associated with treatment resistance. Only adherent patients were included to rule out non-compliance as a confound.
How They Did This
Cross-sectional study of 230 schizophrenia patients at a psychiatric hospital in Khyber Pakhtunkhwa, Pakistan. Clinical evaluation using PANSS and CGI scales. Treatment resistance defined as failure to respond to two adequate antipsychotic trials. Adherent patients only.
Why This Research Matters
Treatment-resistant schizophrenia is one of the most challenging conditions in psychiatry. If cannabis use contributes to treatment resistance, it identifies a modifiable factor that could improve outcomes for a substantial number of patients.
The Bigger Picture
This finding from a region with prevalent cannabis use adds international evidence to the cannabis-schizophrenia relationship. The focus on treatment resistance (rather than just onset or relapse) identifies a clinically important and potentially actionable pathway.
What This Study Doesn't Tell Us
Cross-sectional design cannot establish causation. Self-reported cannabis use may be underreported. The heavily male cohort limits generalizability. Specific cannabis types, doses, and duration of use were not detailed. High treatment resistance rate may reflect referral bias at a tertiary hospital.
Questions This Raises
- ?Does cannabis cessation restore treatment responsiveness?
- ?Is the association specific to certain antipsychotics?
- ?Would the same pattern appear in female patients or other populations?
Trust & Context
- Key Stat:
- >60% treatment resistant
- Evidence Grade:
- Rated moderate because the study had a reasonable sample size and controlled for adherence, but the cross-sectional design limits causal inference.
- Study Age:
- Published in 2019. Data from a region in Pakistan with prevalent cannabis use.
- Original Title:
- Association of smoked cannabis with treatment resistance in schizophrenia.
- Published In:
- Psychiatry research, 278, 242-247 (2019)
- Authors:
- Arsalan, Arsalan, Iqbal, Zafar, Tariq, Muhammad, Ayonrinde, Oyedeji, Vincent, John B, Ayub, Muhammad
- Database ID:
- RTHC-01923
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Does cannabis make schizophrenia harder to treat?
This study found an association between ongoing cannabis use and treatment resistance in schizophrenia patients who were otherwise taking their medications as prescribed.
What is treatment-resistant schizophrenia?
When symptoms do not adequately improve after trying at least two different antipsychotic medications at adequate doses and duration.
Could stopping cannabis improve treatment response?
The study did not test this directly, but the association suggests cannabis cessation could be worth investigating as a strategy to improve treatment outcomes.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01923APA
Arsalan, Arsalan; Iqbal, Zafar; Tariq, Muhammad; Ayonrinde, Oyedeji; Vincent, John B; Ayub, Muhammad. (2019). Association of smoked cannabis with treatment resistance in schizophrenia.. Psychiatry research, 278, 242-247. https://doi.org/10.1016/j.psychres.2019.06.023
MLA
Arsalan, Arsalan, et al. "Association of smoked cannabis with treatment resistance in schizophrenia.." Psychiatry research, 2019. https://doi.org/10.1016/j.psychres.2019.06.023
RethinkTHC
RethinkTHC Research Database. "Association of smoked cannabis with treatment resistance in ..." RTHC-01923. Retrieved from https://rethinkthc.com/research/arsalan-2019-association-of-smoked-cannabis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.